KRMD KORU Medical Systems, Inc. Insider Trading

President-Chief Commercial Officer Adam Kalbermatten purchases 12,500 shares for $49,275.00 at KRMD; holdings rise to 312,500 shares.

Adam Kalbermatten executed 2 purchases totaling 12,500 shares for $49,275.00, bringing his post-transaction holdings to 312,500 shares (+4.2% vs pre-transaction holdings of 300,000 shares). The blended average purchase price of $3.94 trades above the current price of $3.87, while the stock remains -41.4% from its 52-week high of $6.61. KRMD is unprofitable on a full-year basis with net income of $-807,078.00 in the latest quarter, though the company posted annual revenue growth of +22.2% and a market cap of $177,760,710.00. The transaction occurred as the stock has declined 9.4% over the past 90 days, presenting context for an officer-level accumulation by a senior commercial executive.

CTO Schiller purchases 5,000 KRMD shares at $3.91; cluster buy by 4 insiders in 14 days as stock trades -39.5% from 52-week high

Eric Schiller, Chief Technology Officer, initiated a new position by purchasing 5,000 shares at $3.91 on 2026-05-18. This transaction is part of a cluster pattern: 3 other insiders also bought within the same 14-day window. The company is trading at $4.00, down -39.5% from its 52-week high of $6.61 and down -14.7% over the past 90 days, while the stock has declined -6.1% in the past 30 days. Despite revenue growth of +22.2% year-over-year, the company reported a net loss of $-807.1K in its most recent quarter and was unprofitable over its most recent full fiscal year. The concurrent buying activity by multiple insiders at a depressed price level warrants examination of whether this reflects management confidence, opportunistic entry during a pullback, or routine portfolio actions unrelated to company fundamentals.

COO Pazdan Christopher purchases 5,000 shares of KRMD at $3.88; stock down 42.1% from 52-week high

Pazdan Christopher, Chief Operating Officer, purchased 5,000 shares at $3.88 on 2026-05-14, bringing his holdings to 305,131 shares. The stock is currently priced at $3.83, approximately 42.1% below its 52-week high of $6.61, and has declined 11.6% over the past 30 days and 18.0% over the past 90 days. The company generated revenue of $11,764,624.00 in its latest quarter with annual revenue growth of 22.2%, but reported a net loss of $-807,078.00 and remains unprofitable on a full-year basis. The purchase occurred against a backdrop of significant price weakness and persistent unprofitability, which frames the transaction within the company's current operating and market conditions.

Then-CFO Adams buys 5,500 shares for $21,248.36 at $3.86 blended avg; holds 308,147 shares post-transaction.

Adams Thomas Edward, who was CFO at the time, purchased 2 separate tranches totaling 5,500 shares (5.5K shares) for $21,248.36 ($21.2K) on 2026-05-14, raising his holdings from 302,647 shares to 308,147 shares (a +1.8% increase). The company's most recent quarter showed revenue of $11,764,624.00 ($11.8M) but net income of $-807,078.00 ($-807.1K), and annual revenue growth was +22.2% despite full-year unprofitability. The stock is currently trading at $3.83, down -42.1% from its 52-week high of $6.61 and down -11.6% over the prior 30 days. An insider open-market purchase by a then-officer during a period of material price decline and operating losses warrants review of the transaction's context and any contemporaneous developments at the company.